[工作场所的疫苗接种和不良事件赔偿]。

Q3 Medicine Journal of UOEH Pub Date : 2022-01-01 DOI:10.7888/juoeh.44.177
Tatsunori Suemitsu, Shogo Miyazaki, Kazuto Sato, Yutaro Hashimoto
{"title":"[工作场所的疫苗接种和不良事件赔偿]。","authors":"Tatsunori Suemitsu, Shogo Miyazaki, Kazuto Sato, Yutaro Hashimoto","doi":"10.7888/juoeh.44.177","DOIUrl":null,"url":null,"abstract":"<p><p>Several types of SARS-Cov-2 vaccine have been quickly developed and officially approved for emergency use in accordance with the Pharmaceutical Act. Mass vaccination in workplaces in Japan was subsequently promoted, targeting health care workers and senior citizens. We overviewed the pathophysiology of COVID-19 and reviewed reports containing fatal outcomes, compensation programs, and remedial measures for health damage after vaccinations, in relation to their relevant legislations. The Immunization Act was amended prior to the mass vaccination to authorize the indemnity agreement between the government and pharmaceutical companies to compensate for losses based on health damages after vaccination. Pursuant to the Civil Code and the State Redress Act, employers reserve the right to obtain reimbursement when they are liable to pay compensation for damages inflicted on a third party. There are no provisions to exclude healthcare workers and occupational health staff who participated in practical procedures from lawsuits and liability. We propose legislative reformation and careful contracts with responsible organizations concerned with emergency vaccinations in order to confront forthcoming new or re-emerging infections beyond this pandemic.</p>","PeriodicalId":17570,"journal":{"name":"Journal of UOEH","volume":"44 2","pages":"177-184"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Vaccination in Workplace and Compensation for Adverse Events].\",\"authors\":\"Tatsunori Suemitsu, Shogo Miyazaki, Kazuto Sato, Yutaro Hashimoto\",\"doi\":\"10.7888/juoeh.44.177\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Several types of SARS-Cov-2 vaccine have been quickly developed and officially approved for emergency use in accordance with the Pharmaceutical Act. Mass vaccination in workplaces in Japan was subsequently promoted, targeting health care workers and senior citizens. We overviewed the pathophysiology of COVID-19 and reviewed reports containing fatal outcomes, compensation programs, and remedial measures for health damage after vaccinations, in relation to their relevant legislations. The Immunization Act was amended prior to the mass vaccination to authorize the indemnity agreement between the government and pharmaceutical companies to compensate for losses based on health damages after vaccination. Pursuant to the Civil Code and the State Redress Act, employers reserve the right to obtain reimbursement when they are liable to pay compensation for damages inflicted on a third party. There are no provisions to exclude healthcare workers and occupational health staff who participated in practical procedures from lawsuits and liability. We propose legislative reformation and careful contracts with responsible organizations concerned with emergency vaccinations in order to confront forthcoming new or re-emerging infections beyond this pandemic.</p>\",\"PeriodicalId\":17570,\"journal\":{\"name\":\"Journal of UOEH\",\"volume\":\"44 2\",\"pages\":\"177-184\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of UOEH\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7888/juoeh.44.177\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of UOEH","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7888/juoeh.44.177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

根据《药品法》,几种 SARS-Cov-2 疫苗已被迅速开发并正式批准用于紧急用途。随后,日本针对医护人员和老年人在工作场所推广了大规模疫苗接种。我们对 COVID-19 的病理生理学进行了综述,并结合相关立法对包含致命结果、补偿计划和接种疫苗后健康损害补救措施的报告进行了审查。在大规模疫苗接种之前,对《免疫法》进行了修订,授权政府与制药公司签订赔偿协议,对疫苗接种后造成的健康损害进行赔偿。根据《民法》和《国家补偿法》,当雇主有责任为第三方造成的损害支付赔偿时,他们保留获得补偿的权利。没有任何规定将参与实际操作的医护人员和职业卫生工作人员排除在诉讼和赔偿责任之外。我们建议进行立法改革,并与负责紧急疫苗接种的相关组织签订谨慎的合同,以应对此次大流行之后即将出现的新的或再次出现的感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Vaccination in Workplace and Compensation for Adverse Events].

Several types of SARS-Cov-2 vaccine have been quickly developed and officially approved for emergency use in accordance with the Pharmaceutical Act. Mass vaccination in workplaces in Japan was subsequently promoted, targeting health care workers and senior citizens. We overviewed the pathophysiology of COVID-19 and reviewed reports containing fatal outcomes, compensation programs, and remedial measures for health damage after vaccinations, in relation to their relevant legislations. The Immunization Act was amended prior to the mass vaccination to authorize the indemnity agreement between the government and pharmaceutical companies to compensate for losses based on health damages after vaccination. Pursuant to the Civil Code and the State Redress Act, employers reserve the right to obtain reimbursement when they are liable to pay compensation for damages inflicted on a third party. There are no provisions to exclude healthcare workers and occupational health staff who participated in practical procedures from lawsuits and liability. We propose legislative reformation and careful contracts with responsible organizations concerned with emergency vaccinations in order to confront forthcoming new or re-emerging infections beyond this pandemic.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of UOEH
Journal of UOEH Medicine-Medicine (all)
CiteScore
1.30
自引率
0.00%
发文量
35
期刊介绍: Published quarterly: 1 annual volume consisted of 4 numbers. Issued on the 1st of March, June, September and December, respectively.
期刊最新文献
Digital Occupational Health: Opportunities and Challenges for the Workplace. Examination of Permeation Resistance of Chemical Protective Gloves Made of Laminate-Film Materials Against Chemical Substances. Health Transformation in Indonesia Through Health Digitalization Strengthening: A Perspective From Occupational Health. Occupational Health and Safety Digitalization in Thailand: A Framework and Case Study. Occupational Medicine, Go Above and Beyond.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1